Shabalov V 1,Tomskiy A 1, Gamaleya A 1,2, Orlova O 3, Timerbaeva S 4, Isagulyan E 1, Dekopov A 1, Salova E 1, Fedorova N 2 1 Functional Neurosurgery Group,

Slides:



Advertisements
Similar presentations
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Advertisements

Drugs and Treatments for Ataxia Christopher M. Gomez The University of Chicago.
Martha J. Morrell MD NeuroPace, Inc.
Deep Brain Stimulation Sam Park Treatment of Parkinson’s Disease.
Spinal Cord Stimulation for Painful Legs and Moving Toes Syndrome Marie-Pierre Fournier-Gosselin MD 1, Rosalind S Chuang MD 2, Anthony E Lang MD 2, Cristina.
Complications of Deep Brain Stimulation: Risks of Placement vs Neurostimulator Device Issues Shahid M. Nimjee, MD, PhD Isaac O. Karikari, MD Tiffany R.
By Lisa Rosenberg Deep Brain Stimulation. Electrical probe implanted in brain Approved by FDA in mid 1990’s Hidden under skin Does not damage healthy.
Katie Rousseau Erich Richter, M.D. LSU Health Sciences Center, New Orleans.
Deep Brain Stimulation
Relationship Between Donor Graft Cell Count and Visual Outcome in DSAEK Patients Authors Silvin Bakalian MD PhD, Johanna Choremis MD FRCSC, Michele Mabon.
N. Camden Kneeland, M.D., D.A.B.A.
Long-term Outcomes of an Interdisciplinary Weight Management Clinic for Youth with Special Needs Meredith Dreyer Gillette PhD 1, 2, Cathleen Odar Stough.
Surgery For Parkinson’s Disease Current Practice and Future Directions
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
Successful Treatment of Low Back Pain with a Novel Neuromodulation Device Iris Smet, MD 1 Jean-Pierre Van Buyten, MD 1 Adnan Al-Kaisy MB ChB FRCA 2 1 AZ.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
ASYMMETRIES IN rsFMRI INTRINSIC BRAIN ACTIVITY MEASURES AS A PREDICTOR OF EPILEPSY SURGERY SUCCESS Carly M. Rosen, David M. Groppe, Ashesh D. Mehta Laboratory.
JAHDIEL FRANCO BME 482 Deep Brain Stimulation for Psychiatric Disorders.
Ranjith Babu, MS 1 Jonathan Choi, MD 1 Adam Back, MD 1 Vijay Agarwal, MD 1 Matthew Hazzard, MD 1 Beatrice Ugiliweneza, MSPH PhD 2 Chirag G. Patil, MD MS.
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Overview of Neurostimulation
TECHNOLOGY IN REHABILITATION
Julia Fischer, Kati Schwiecker, Verena Bittner, Imke Galazky, Hans-Jochen Heinze, Jürgen Voges, Tino Zaehle Departments of Neurology and Stereotactic Neurosurgery,
Tang G et al. Proc SABCS 2010;Abstract S4-9.
Deep Brain Stimulation (DBS) Ramin AmirNovin, MD LDR Neurosurgery and Associates.
The Surgical Treatment of Parkinson’s Disease
Outcome after Total Knee Arthroplasty in the Patients with Psychologic Disorder Nam-Hong Choi, M.D. Young-Eun Park, M.D. Knee & Shoulder service Department.
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Neuromodulation for chronic intractable primary headache Laurence Watkins Victor Horsley Department of Neurosurgery National Hospital for Neurology & Neurosurgery.
MRI guided Focused Ultrasound
Aaron Mulheren, Kathryn Wilson, MSN, APN, Milind Deogaonkar, MD
Non-motor symptoms of Parkinson’s disease This educational material has been supported by Abbott.
Case Presentation: DBS for Depression Robert McGovern, MS-IV Neurosurgery Grand Rounds, Massachusetts General Hospital July 16 th, 2009.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
The Effects of Deep Brain Stimulation on the Motor Symptoms of Parkinson’s Disease Aaron Mulheren Kathryn Wilson, MSN, APN Milind Deogaonkar, MD Science.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Dr.Khabti Muhanna Mr.Khalid Alaqeel Department of Otolaryngology,
Therapeutic and diagnostic protocol for the treatment of scoliosis associated with Syringomyelia Francesco Lolli, Konstantinos Martikos, Francesco Vommaro,
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Adaptive randomization
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
Responsive Neurostimulation (RNS) for the treatment of epilepsy
Intensity-Modulated Radiotherapy is Associated with Improved Global Quality of Life Among Long-Term Survivors of Head and Neck Cancer Allen M. Chen, M.D.,
Transcranial Magnetic Stimulation (TMS)
Irina Vasilyeva, Moscow, Russia Russian National Research Medical University Clinical and Research Institute of Emergency Children’s Surgery and Trauma.
Combination of Frameless Navigation and Intraoperative Neurophysiology for Motor Cortex Stimulation Konstantin Slavin, MD, and Keith R. Thulborn, MD, PhD.
Long-Term Complications and Mortality in Young-Onset Diabetes Type 2 diabetes is more hazardous and lethal than type 1 diabetes Featured Article: Maria.
John T. Wilkinson m. d. , Chad E. Songy m. d. , Frances l
Clinical Epidemiology and Evidence-based Medicine Unit FKUI – RSCM
DBS management of Tourette's
: Intermittent Neurogenic Claudication Aperius ® Percutaneous Interspinous Spacer F. Collignon, P. Fransen, D Morelli, N. Craig, J. Van Meirhaeghe For.
Department of Neuroendovascular Therapy, Kohnan Hospital, Sendai, Japan Ryushi Kondo, Yasushi Matsumoto Department of Neurosurgery, Kohnan Hospital Satoru.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
PHQ-9 Severity and Screening Tests Predictive of Remission Outcomes at Six Months Kurt B. Angstman, MS MD Associate Professor John M. Wilkinson Assistant.
Important questions As good or better ? Cost effective ? Overall, safer? Is it safe as a cancer operation? Can all surgeons do it? Compare to open surgery.
Background Information Epilepsy is a neurological disorder that characterized by recurrent seizures. It is estimated to affect over 70 million people.
Acetyl Hexapeptide-8 for Treatment of Blepharospasm Codrin Lungu, MD Medical Neurology, NINDS, NIH.
A Survey of the Clinical State and Programming Patterns of Movement Disorder Patients with Impending DBS Battery Power Failure K.M. Wilson RN, R. Mehanna.
Deep Brain Stimulation: A Proven Treatment for Movement Disorders
The NeuroPace RNS® System and Surgical Options
Spinal Cord Stimulation (SCS): A proven surgical option for chronic pain Jeffrey M. Epstein, M.D. Babylon, NY.
Synergetic effect of Intrathecal Baclofen and Deep Brain Stimulation in treating Dystonia 51 Authors Yasser Awaad, MD, MSc, FAAN, FAAP 1&2 & Tamer Rizk,
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Rhematoid Rthritis Respiratory disorders
Treating to Target in MS
A.S.David, R.McCormack and Lishman Unit MDT
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Deep Brain Stimulation: What, When, Why, How
Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis Brian.
Presentation transcript:

Shabalov V 1,Tomskiy A 1, Gamaleya A 1,2, Orlova O 3, Timerbaeva S 4, Isagulyan E 1, Dekopov A 1, Salova E 1, Fedorova N 2 1 Functional Neurosurgery Group, Burdenko Neurosurgical Institute, Moscow, Russian Federation 2 Center for Extrapyramidal Disorders, Russian Medical Academy of Postgraduate Education, Moscow 3 Moscow Medical Sechenov Academy 4 Neurological Research Center, Russian Academy of Medical Scienses, Moscow 14th Annual Meeting Neuromodulation Las-Vegas, US,Hannover, December 2-5, 2010 DBS of GPI in Cases of Primary Generalized and Segmental Dystonia with Different Age of Onset

DBS & DYSTONIA DBS of GPi is considered as a preferable therapy in disabling primary dystonia particular outcomes remain varying and unpredictable search for the prognostic criteria

Isaias IU et al., Brain 2008 Disease duration showed a significant correlation with DBS outcome at 3 and12 months. Vasques X et al., J. Neurosurg 2009 Prognostic value of globus pallidus internus volume in primary dystonia Borggraefe I et al., Brain Dev Predictive factors for a better treatment outcome DYT1-positive status and minor motor impairment before surgery

Objective  to evaluate the efficacy of DBS of GPi at a single center  to reveal possible predictors of clinical improvement in different types of dystonia

Materials and Methods 31 patients with medically refractory primary dystonia 10 males and 21 females DYT1 + 3 patients Prior destructive surgery: pallidotomy in 1 case thalamotomy 3 cases bilateral implantation of pallidal electrodes for continuous high- frequency stimulation

DYSTONIAgeneralized (PGD)segmental (PSD) patients16 patients15 patients age of onset12.4±9.0 years***31.7±15.9 years age at surgery27.8±14.5 years**42.3±13.3 years disease duration15.4±13.5 years10.7±8.8 years Initial BFMDRS47.1±15.3***20.4±5.8 Patients: PGD vs. PSD

Surgical technique 1 step – Stereotactic implantation of the leads, without microelectrode recording, intraoperative test-stimulation in awake patient if possible 2 step – Postoperative control (MRI, test-stimulation) 3 step – Implantation of pulse generator 4 step – Postoperative management

Complications Migration of pulse generator in 2 cases  correction of generator position Electrode dislocation in to incorrect position - 1 case Correction of primary electrode position - 2 cases Dysarthria under DBS - 3 cases Feeling of the leg tension - 2 cases Distal arm dystonia aggravation - 1 case

Results: clinical improvement Mean clinical improvement in BFMDRS motor score in total primary dystonia group (Δ%): – at 3-6 months Δ 53.4±16.0%, – at 9-12 months Δ 64.4±18.5%, – at last follow-up Δ 64.3±19.1% (20.0±13.3 months) P<0.001

Results: Global Outcome Scale scores (Lozano 2000) 0 – no effect 1 – minimal relief without improvement of function 2 – moderate relief with or without minimal improvement of function 3 – moderate relief with improvement of function 4 – significant relief with significant improvement of function 0p – no effect 1p – minimal relief without improvement of function 2p – moderate relief with or without minimal improvement of function 3p - moderate relief with improvement of function 4p – significant relief with significant improvement of function Generalized dystonia Segmental dystonia Total group

Factors Age of disease onset Age of disease onset Gender Gender Disease duration Disease duration Age at surgery Age at surgery Severity of motor function impact Severity of motor function impact (BFMDRS motor score before surgery, PGD vs. PSD)

Factors Age of disease onset Age of disease onset Gender Gender Disease duration Age at surgery Age at surgery Severity of motor function impact Severity of motor function impact (BFMDRS motor score before surgery, PGD vs. PSD)

Results: clinical improvement & disease duration Advantageous outcome both at early and long-term follow-up was associated with minor disease duration rs=-0.546, p=0.002

DYSTONIAchildhood-onset (<12 years) juvenile-onset (12-26 years) adult-onset (>26 years) patients12 patients8 patients11 patients PGD vs. PSD11PGD / 1PSD4PGD / 4PSD1PGD / 10PSD BFMDRS initial51.1±14.8***26.0± ±6.9 disease duration19.8±14.5*8.6±4.99.2±8.2 age at surgery27,4± ± ±3.0 Patients: age of onset

Results: clinical improvement & age of onset Δ 54.7%* P<0.05 ±20.0 Δ 54.7±20.0%* P<0.05 ±14.8 Δ 73.7±14.8% ±18.1 Δ 68.9±18.1%

Clinical improvement in patients with childhood-onset (10 patients) ±9.0 Δ72.1±9.0%, p<0.06 ±16.5 Δ 45.9±16.5%

Conclusions   DBS of GPi is effective in primary dystonia with sustained significant clinical improvement in generalized as well as in segmental forms in equal proportions   Pure DBS of GPi motor outcome (final BFMDRS score) in generalized compared to segmental dystonia remains respectively worse  Age of onset, age at surgery, gender, initial severity are not of a predictive significance  Disease duration is an important efficacy predictor   DBS of GPi may be recommended to be performed early enough in the course of intractable PGD and PSD   Studies pooling together more patients are still needed